N-Zyme Biomedical
N-Zyme Biomedical
A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.
About
N-Zyme Biomedical is a clinical-stage biotechnology company developing first-in-class therapies that target pepsin, a key driver of tissue damage in reflux disease. The company's lead drug candidate, NZ-101, is currently in Phase 2 clinical trials for laryngopharyngeal reflux (LPR) and proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). N-Zyme Biomedical aims to transform the treatment of reflux disease by addressing its underlying causes rather than solely focusing on acid suppression. Teams look it up for Biotechnology, Pharmaceuticals, HealthTech.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.
“N-Zyme Biomedical Begins Phase 2 Trial of First Pepsin Inhibitor for Reflux Disease. What does this mean? Are they closer to the drug?”
View on RedditSome comments are pulled from public discussions around the web (look for the source icon). Quotes are excerpts; click through to read the full thread.
